Alzheimer’s Panel & Report
Overview
- Alzheimer’s disease is a progressive neurodegenerative disorder that impacts memory, cognition, and quality of life. Today, an estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s dementia, a number projected to rise to 13.8 million by 2060. While symptoms often emerge later in life, the underlying biological changes begin decades earlier.
- By analyzing a broad range of gene variants, this panel helps identify risk before symptoms arise empowering both providers and patients to take proactive steps.
What This Test Covers
Our Panel is structured into six key categories, each addressing distinct pathways
that influence Alzheimer’s disease risk and cognitive health:
Neurodegenerative Risk Genetics
Analyzes genetic susceptibility to hallmark mechanisms of Alzheimer’s disease:
- Clusterin-Associated Alzheimer’s Risk
- Overall Alzheimer’s Disease Susceptibility
- APOE Risk Scoring for Alzheimer Disease
Microbiome–Cognitive Health Profile
Explores the genetic connection between gastrointestinal health and cognitive function:
- Gut-Brain Resilience
Alzheimer’s Metabolic Risk Indicators
Evaluates genetic interactions between metabolic function and Alzheimer’s progression:
- Alzheimer’s Disease–Metabolic Interaction (AD-MI)
Homocysteine Regulation
Assesses the genetic ability to regulate homocysteine, a biomarker tied to oxidative stress and neurovascular damage:
- Homocysteine Elevation
Neuro-Immune Health
Analyzes inflammatory response genes linked to brain degeneration:
- Chronic Inflammation
Nutrient Metabolism Profiles
Evaluates metabolism of key neuroprotective nutrients:
- Zinc
- Vitamin D
Why It Matters
Early detection of genetic risk can be a game-changer allowing for preventive strategies that delay or reduce disease progression. The Alzheimer’s Panel helps address this urgency by offering:
- A proactive lens into long-term cognitive risk, years before clinical signs appear
- Precision insights across neuroinflammation, metabolism, and nutrient pathways
- Prevention-first protocols for integrative, functional, and conventional medical approaches
- Greater clarity for dementia clinics, neurologists, geriatric specialists, and cognitive health providers
Who Should Take This Test
This panel is ideal for:
Adults with a family history of Alzheimer’s or dementia seeking proactive risk assessment.
Individuals experiencing early signs of cognitive decline or memory concerns.
Functional and integrative medicine practitioners addressing brain aging at the root.
Neurologists and dementia clinics integrating genomics into diagnostic protocols
Providers supporting patients with brain fog, emotional changes, or mood shifts
Anyone seeking to personalize brain health plans with precision-based insights
What You’ll Receive
Comprehensive Genetic Report
Organized into clear categories and subcategories, covering key health areas with clear polygenic risk interpretations (Low, Medium, High) for each category.
Personalized Insights
A clean report layout with category, subcategory, and SNP-wise interpretation (based on provider or client preference), with personalized insights for nutrition and supplement strategies, lifestyle modifications, and lab tests to consider for monitoring cognitive risk.
Provider Portal Access
Secure digital access via the ExtendingME Provider Portal for seamless report viewing, sharing.
Turnaround Time
Results will be available within 3 weeks from the receipt of the sample and will be securely delivered through the Provider Portal, enabling seamless access, viewing, and sharing of reports.
Collection Method
ExtendingME kits include all necessary self-collection devices for non-invasive, at-home saliva collection, making it easy to deliver real-time, data-driven healthcare solutions without the need for lab visits.
Take Action Before Symptoms Start
Early genetic insights. Smarter prevention. Personalized brain health powered by your DNA.
